



Chemours™

LANXESS acquires Chemours' Clean & Disinfect business

Complementing portfolio of customer solution businesses

Matthias Zachert, CEO
Michael Pontzen, CFO

LANXESS
Energizing Chemistry

Safe harbor statement

The information included in this presentation is being provided for informational purposes only and does not constitute an offer to sell, or a solicitation of an offer to purchase, securities of LANXESS AG. No public market exists for the securities of LANXESS AG in the United States.

This presentation contains certain forward-looking statements, including assumptions, opinions and views of the company or cited from third party sources. Various known and unknown risks, uncertainties and other factors could cause the actual results, financial position, development or performance of LANXESS AG to differ materially from the estimations expressed or implied herein. LANXESS AG does not guarantee that the assumptions underlying such forward-looking statements are free from errors nor does it accept any responsibility for the future accuracy of the opinions expressed in this presentation or the actual occurrence of the forecast developments. No representation or warranty (expressed or implied) is made as to, and no reliance should be placed on, any information, estimates, targets and opinions, contained herein, and no liability whatsoever is accepted as to any errors, omissions or misstatements contained herein, and accordingly, no representative of LANXESS AG or any of its affiliated companies or any of such person's officers, directors or employees accept any liability whatsoever arising directly or indirectly from the use of this document.

Acquisition of highly attractive biocide and customer solution business – perfect fit for our BU Material Protection Products

Chemours' Clean & Disinfect business

Virkon™

- Globally #1 powder veterinary disinfectant
- Target market ~€500 m

Oxone™

- Globally #1 in monopersulfate
- Key ingredient for Virkon™ and sales in adjacent industries (e.g. pool & spa)

Chlorine Dioxide business for industrial water treatment




Animal health



Pool & spa



Human health



Electronics

Sales
~€100 m*

EBITDA
~€20 m*

Employees
~170

Production
3 sites

Significant expansion of high margin biocide business with attractive growth rates (3-6%)

Market access into attractive niche veterinary disinfection market with potential of top-line synergies


Chemours' (formerly DuPont) business is the only backward integrated player

* Financials FY 2015 pro forma pre exceptionals; FX: 1.10 USD/EUR

Customer solution business at BU MPP – a leading player in a highly attractive niche market

BU MPP – an attractive niche business within Performance Chemicals

LANXESS



Illustrative

BU MPP – a leading biocide producer

- Portfolio offers a wide range of products for microbial control in wood protection, paints & coatings, beverages and disinfection
- Global footprint established with assets in Europe, North America and Asia
- BU sales: Stepping up from ~€200 m to ~€300 m by acquisition


Biocides Market – a highly attractive niche market

- Data packages and expertise in regulatory affairs are key elements to participate in the biocide market
- Technical expertise for customer solutions critical
- Low capital intensity business with attractive growth rates
- Peers: Lonza, Troy, Thor

BU MPP with expanded scale, global sales and distribution power

LANXESS

Strong strategic fit: enlarging application fields and strengthening the value chain at the same time



Attractive valuation for a customer solution business

Attractive Valuation

**EV/EBITDA excluding synergies
~10.5x**

**EV/EBITDA including synergies
~7.0x**

**EPS accretive in
year 1**



Transaction details

- 2015 sales: ~€100 m
- 2015 EBITDA: ~€20 m
- Expected synergies of ~€10 m EBITDA by 2020
- Enterprise value: ~€210 m
- Enterprise value including tax benefit: ~€190 m
- Financed through existing liquidity
- Closing expected in H2 2016; subject to approval from anti-trust authorities

All financials 2015 pro forma pre exceptionals, FX: 1.10 USD/EUR

Strong strategic fit and financially attractive deal – a strategic step to grow the more resilient and valuable New LANXESS

Swift delivery of strategy to grow resilient businesses

**Excellent strategic fit with a strengthened value chain
and top line synergies**

Attractive valuation for a specialty business



LANXESS

A thick red horizontal bar is positioned below the word "LANXESS", starting from the left edge of the letter "L" and extending to the right edge of the letter "N".

Rationale: Acquisition will accelerate the disinfection business at LANXESS

Key Value Drivers



Increasing product portfolio: Leadership position in attractive animal biosecurity segment

- Virkon™ is the leading powder veterinary disinfectant
- Backward integration into key active ingredient Oxone™ provides leadership position in veterinary disinfection market



Synergies through forward integration of existing LANXESS disinfectant portfolio

- Enhancement of integrated value chain: From active ingredient to end product
- Excellent starting point to promote and expand use of existing disinfectant portfolio with acquired extensive distribution network

Biocide Market

Attractive growth drivers
(3-6% market growth)

Low capital intensity

High regulatory barriers

Contact details Investor Relations

Oliver Stratmann

Head of Treasury & Investor Relations

Tel. : +49-221 8885 9611
Fax. : +49-221 8885 5400
Mobile : +49-175 30 49611
Email : Oliver.Stratmann@lanxess.com



Janna Günther

Assistant to Oliver Stratmann

Tel. : +49-221 8885 9834
Fax. : +49-221 8885 4944
Mobile : +49-151 74612615
Email : Janna.Guenther@lanxess.com



LANXESS IR website



Ulrike Rockel

Head of Investor Relations

Tel. : +49-221 8885 5458
Mobile : +49-175 30 50458
Email : Ulrike.Rockel@lanxess.com



Matthias Arnold

Institutional Investors / Analysts

Tel. : +49-221 8885 1287
Mobile : +49-151 74612343
Email : Matthias.Arnold@lanxess.com



Katharina Forster

Institutional Investors / Analysts / AGM

Tel. : +49-221 8885 1035
Mobile : +49-151 74612789
Email : Katharina.Forster@lanxess.com



Dirk Winkels

Institutional Investors / Analysts

Tel. : +49-221 8885 8007
Mobile : +49-175 30 58007
Email : Dirk.Winkels@lanxess.com

